THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands ( www.guidetopharmacology.org ), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14747 . In addition to this overview, in which are identified Other protein targets which fall outside of the subsequent categorisation, there are six areas of focus: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

[1]  Souvik Banerjee,et al.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy , 2019, Medicinal research reviews.

[2]  Maija Dambrova,et al.  Allosteric Modulators of Sigma-1 Receptor: A Review , 2019, Front. Pharmacol..

[3]  Habibeh Khoshbouei,et al.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. , 2018, Pharmacology & therapeutics.

[4]  Mark P. Mattson,et al.  Notch signaling and neuronal death in stroke , 2018, Progress in Neurobiology.

[5]  Carsten Janke,et al.  Tubulin Posttranslational Modifications and Emerging Links to Human Disease , 2018, Cell.

[6]  Shelley B Hooks,et al.  Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. , 2018, Cellular signalling.

[7]  Diego Bonatto,et al.  Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆ , 2017, Pharmacology & therapeutics.

[8]  Carsten Janke,et al.  The tubulin code at a glance , 2017, Journal of Cell Science.

[9]  B. Sjögren,et al.  The evolution of regulators of G protein signalling proteins as drug targets – 20 years in the making: IUPHAR Review 21 , 2017, British journal of pharmacology.

[10]  Shang-Yi Tsai,et al.  The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. , 2016, Trends in pharmacological sciences.

[11]  Franz Oswald,et al.  The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. , 2016, Biochimica et biophysica acta.

[12]  C. Rousseaux,et al.  Sigma receptors [σRs]: biology in normal and diseased states , 2015, Journal of receptor and signal transduction research.

[13]  Wu-Min Deng,et al.  Ligand-Independent Mechanisms of Notch Activity. , 2015, Trends in cell biology.

[14]  Michael Kahn,et al.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update , 2015, Nature Reviews Clinical Oncology.

[15]  D. Zamanillo,et al.  Sigma-1 receptor and inflammatory pain , 2015, Inflammation Research.

[16]  Anil K Sood,et al.  Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer , 2014, Clinical Cancer Research.

[17]  Richard R Neubig,et al.  Thinking Outside of the “RGS Box”: New Approaches to Therapeutic Targeting of Regulators of G Protein Signaling , 2010, Molecular Pharmacology.

[18]  Douglas M. Yau,et al.  Non-canonical functions of RGS proteins. , 2010, Cellular signalling.

[19]  Richard R. Neubig,et al.  Regulators of G-Protein signalling as new central nervous system drug targets , 2002, Nature Reviews Drug Discovery.